MedTrace Logo

eVusheld Assessment reaL wORld Effectiveness in the VA Health System

NCT05663957 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5814

Last updated 2024-09-03

No results posted yet for this study

Summary

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the Department of Veterans Affairs (VA) Health System.

Conditions

  • SARS-CoV-2, COVID-19

Interventions

DRUG

Evusheld

EVUSHELD users

Sponsors & Collaborators

  • VA Informatics and Computing Infrastructure (VINCI)

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Scott L DuVall, PhD · VA Informatics and Computing Infrastructure (VINCI)

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-04
Primary Completion
2023-09-01
Completion
2023-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663957 on ClinicalTrials.gov